Indegene Limited has informed the Exchange about Analyst presentation and fact sheet on financial results for the quarter ended June 30, 2025.
INDGN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Indegene filed its Q1 FY26 analyst presentation and fact sheet with the exchanges. Revenue from operations came in at INR 7,608 Mn ($88.9 Mn), up 0.7% QoQ in INR and 1.8% QoQ in USD, with YoY growth of 12.5%. EBITDA margin was stable at 20.2% (INR 1,536 Mn) and PAT margin was 15.3% (INR 1,164 Mn), up 2.3 percentage points YoY. Management highlighted stable and profitable growth, a strong cash balance of INR 17,280 Mn, and ongoing focus on M&A in Data & Analytics and Medical capabilities, with a dedicated team driving this. The Brand Activation segment declined 21.6% QoQ due to project delays and the conclusion of a large engagement, while core segments (Enterprise Commercial Solutions and Enterprise Medical Solutions) grew 3.5% QoQ and 16.8% YoY.
The quarter shows steady execution with stable margins, healthy cash, and visible deal momentum, which is likely to be viewed positively. However, the sharp QoQ drop in Brand Activation and lacklustre QoQ growth may temper near-term enthusiasm, though the focus on Tectonic deals and M&A could act as future growth catalysts for shareholders.